$OCX Last week, Oncocyte announced positive data results for its flagship diagnostic product, VitaGraft™.
In a phase 2 double-blind, placebo-controlled study (NCT05021484), VitaGraft Kidney was used to monitor graft injury associated with the investigational drug felzartamab, a fully human CD38 monoclonal antibody, aimed at treating antibody-mediated rejection (AMR), a leading cause of kidney allograft failure.
VitaGraft Kidney assesses the health of grafts by measuring the amount of donor-derived DNA in the blood of transplant patients, serving as a crucial biomarker.
